Abstract:Introduction The recognition of the key role of angiogenesis for cancer growth has opened new frontiers in oncology1. In cancer therapy, the development of novel drugs aimed at blocking angiogenic processes has spurred the need for imaging biomarkers able to assess and predict the response to therapy. In response, targeted contrast agents have been developed providing selective enhancement in areas of active angiogenesis by binding to specific molecules over-expressed in angiogenic tumor vasculature. In the context of ultrasound molecular imaging (USMI), the first and currently only clinical-translatable targeted ultrasound contrast agent (tUCA) is obtained from conventional UCA by decoration of the microbubble shell with ligands targeting the vascular endothelial growth receptor factor 2 (VEGFR2), over-expressed in several solid tumors1. Assessment of the level of binding has been adopted as an indirect way of quantifying angiogenesis. Semi-quantitatively, this is done by looking at the late-enhancement (LE) several minutes after injection, often in conjunction with the application of a high-pressure US burst to derive the differential targeted enhancement (dTE), i.e., the difference in the acoustic signal before and after the application of the high-pressure burst1,2. For quantitative assessment, we recently proposed pharmacokinetic modeling of the binding kinetics of tUCA by the first-pass binding model (FPB), enabling quantification of angiogenesis by estimation of the microbubble binding rate (Kb)3. Here, we show the feasibility of the method for angiogenesis imaging in 11 rat models of prostate cancer, and for therapy monitoring of colorectal cancer in 17 mice undergoing anti-angiogenic treatment. Methods Time-intensity curves extracted at each pixel/voxel of USMI loops were fitted by the FPB model for estimation of the microbubble binding rate Kb. This was compared to semi-quantitative assessment by LE and dTE for: (i) angiogenesis imaging of prostate cancer by comparing parameter values in cancer and healthy regions of interest (ROIs) in 11 rats; (ii) anti-angiogenic therapy monitoring by comparing parameter values in responders, non-responders, and control mice at 5 time points during anti-angiogenic treatment. Results and Discussion Table I shows the differences in USMI parameters in healthy and tumor ROIs, obtained in 11 prostate-tumor bearing rats. Figure 1 shows the changes in USMI parameters during antiangiogenic treatment, obtained in 17 colorectal cancer-bearing mice. The results suggest the microbubble binding rate Kb to be a promising quantitative biomarker of angiogenesis, enabling the distinction between healthy and cancer tissue, and the early prediction of the response to anti-antiangiogenic therapy.

Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature

Study on Hypovascular Tumor' S Treatment with Targeted Mierobubbles Combined with Ultrasonic Abrupted Destroy

A novel therapeutic strategy using ultrasound mediated microbubbles destruction to treat colon cancer in a mouse model.

An Experimental Research into Endostatin Microbubble Combined with Focused Ultrasound for Anti-Tumor Angiogenesis in Colon Cancer

Characteristics of VEGFR2-targeted Lipid Microbubbles Contrast-Enhanced Ultrasound in Nude Mice with Subcutaneous Colonic Carcinoma Xenografts: Compared with Lipid Microbubbles

Anti-tumor Efficacy of Ultrasonic Cavitation is Potentiated by Concurrent Delivery of Anti-Angiogenic Drug in Colon Cancer

Quantitative Ultrasound Molecular Imaging for Antiangiogenic Therapy Monitoring

Pharmacokinetic modeling of targeted microbubbles: applications in angiogenesis imaging and therapy monitoring

Dual-Targeted Microbubbles Specific to Integrin Αvβ3 and Vascular Endothelial Growth Factor Receptor 2 for Ultrasonography Evaluation of Tumor Angiogenesis.

Breast tumor response to ultrasound mediated excitation of microbubbles and radiation therapy in vivo

Molecular ultrasound imaging with vascular endothelial growth factor receptor 2-targeted microbubbles in a mouse liver cancer model

Non-invasive Monitoring of Ultrasound-Stimulated Microbubble Radiation Enhancement Using Photoacoustic Imaging

Ultrasound Microbubbles for Molecular Diagnosis, Therapy, and Theranostics

Intravital imaging and cavitation monitoring of antivascular ultrasound in tumor microvasculature

Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer

Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues

Ultrasound-stimulated microbubble enhancement of radiation response

Monitoring of anti-angiogenic therapy by quantitative ultrasound molecular imaging

Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy

Ultrasound and Microbubble-Induced Reduction of Functional Vasculature Depends on the Microbubble, Tumor Type and Time After Treatment

Photoacoustic imaging biomarkers for monitoring biophysical changes during nanobubble-mediated radiation treatment